Thiazolidinediones in the treatment of type 2 diabetes.
In the last few years there has been an explosion of research that has improved our understanding of the pathogenesis of Type 2 diabetes mellitus (DM-2) and has led to the development of new oral antidiabetic drugs. Thiazolidinediones (TZDs) are the newest of these antidiabetic agents. TZDs are insulin sensitisers that depend on the presence of insulin for their action. They target insulin resistance, which is thought to play a central role in DM-2 and the associated metabolic syndrome characterised by central obesity, hypertension, dyslipidemia and hypercoagulability, all leading to increased cardiovascular morbidity and mortality. As a result, TZDs have the potential to improve other conditions associated with the metabolic syndrome, in addition to their glycaemic action. TZDs act by activating peroxisome proliferator-activated receptor (PPAR) phi a nuclear receptor implicated not only in lipid and glucose metabolism but other physiological functions as well. TZDs may have wide clinical applications beyond DM-2, as they can potentially be used to treat other conditions associated with insulin resistance and PPAR-phi receptors, such as impaired glucose tolerance, polycystic ovarian syndrome and HIV lipodystrophy.
Pittas
Anastassios G
AG
Tufts University School of Medicine, New England Medical Center, Division of Endocrinology, Diabetes, Metabolism and Molecular Medicine, 750 Washington Street, NEMC#268, Boston, MA 02111, USA. apittas@lifespan.org
Greenberg
Andrew S
AS
D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D007004:Hypoglycemic Agents / Q000191:economics / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000077205:Pioglitazone; D016032:Randomized Controlled Trials as Topic; D000077154:Rosiglitazone; D013844:Thiazoles / Q000191:economics / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use*; D045162:Thiazolidinediones
D007004:Hypoglycemic Agents; D013844:Thiazoles; D045162:Thiazolidinediones; D000077154:Rosiglitazone; C089946:2,4-thiazolidinedione; D000077205:Pioglitazone